Médecine

Paramédical

Autres domaines


S'abonner

Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare - 14/03/12

Doi : 10.1016/j.jaad.2011.01.015 
Inbal Braunstein, MD a, b, Noah G. Goodman, MPH c, Misha Rosenbach, MD b, Joyce Okawa, RN a, b, Asha Shah, MD a, b, Michael Krathen, MD a, b, Carrie L. Kovarik, MD a, b, Eline Luning Prak, MD, PhD c, Victoria P. Werth, MD a, b,
a Dermatology Section, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania 
b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 
c Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 

Reprint requests: Victoria P. Werth, MD, Department of Dermatology, Hospital of the University of Pennsylvania, PCAM Suite 1-330S, 3400 Civic Center Blvd, Philadelphia, PA 19104.

Abstract

Background

Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE).

Objectives

We evaluate the use of lenalidomide in CLE and describe the skin and circulating leukocyte profile of treatment-refractory patients before and after treatment.

Methods

Five subjects were treated with lenalidomide in an unblinded open-label study. Immunohistochemistry of skin was performed for T-cell markers, glycosaminoglycans, and CXCL10, an interferon-inducible chemokine, before and after treatment. Immunophenotyping and measurement of interferon-inducible genes from peripheral blood mononuclear cells was also performed before and after treatment.

Results

Four subjects demonstrated clinical improvement of their skin, however one of these responders subsequently developed symptoms of systemic lupus erythematosus. Small changes in rare circulating leukocyte subsets, plasmacytoid dendritic cells, and regulatory T cells were observed with treatment and may correlate with clinical response. Treatment was associated with increased circulating HLA-DR expression and decreased markers of interferon-mediated pathways, regardless of clinical response.

Limitations

Our results are limited by small sample size and the measurement of rare populations of circulating cell subsets.

Conclusions

Lenalidomide may have usefulness as therapy for severe, treatment-refractory CLE. However, our preliminary data suggest that lenalidomide may activate T cells and trigger systemic disease in some patients with CLE. We also saw a different histologic and circulating leukocyte phenotype in the nonresponding subject. Further characterization of the skin and circulating leukocyte profile of treatment-refractory patients will improve our understanding of CLE.

Le texte complet de cet article est disponible en PDF.

Key words : cutaneous lupus erythematosus, lenalidomide, lupus erythematosus, subacute cutaneous, lupus erythematosus, discoid, lupus erythematosus, tumid

Abbreviations used : CLA, CLASI, CLE, DLE, GAG, IFN, IHC, pDCs, SCLE, SLE, TLE, Tregs


Plan


 Supported in part by the Alliance for Lupus Research, a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (K24-AR 02207) to Dr Werth. Celgene Corporation provided the drug free of charge.
 Conflicts of interest: None declared.


© 2011  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 66 - N° 4

P. 571-582 - avril 2012 Retour au numéro
Article précédent Article précédent
  • Cost-effectiveness analysis of a patient-centered care model for management of psoriasis
  • Kory Parsi, Cindy J. Chambers, April W. Armstrong
| Article suivant Article suivant
  • Novel assay for detecting celiac disease–associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides
  • Michael Kasperkiewicz, Cornelia Dähnrich, Christian Probst, Lars Komorowski, Winfried Stöcker, Wolfgang Schlumberger, Detlef Zillikens, Christian Rose

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.